Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.85+0.04 (+5.13%)
Close on Nov 18, 2026Market cap $109.79MP/E –Yield –
Organogenesis revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Organogenesis's revenue for the twelve months ending Jun 30, 2026 was $457.45M, up 6.5% year over year. For fiscal 2025 it was $564.17M, up 17.0% from the year before. The highest annual figure on record is $564.17M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $564.17M | +17.0% |
| FY2024 | Dec 31, 2024 | $482.04M | +11.3% |
| FY2023 | Dec 31, 2023 | $433.14M | -3.9% |
| FY2022 | Dec 31, 2022 | $450.89M | -3.5% |
| FY2021 | Dec 31, 2021 | $467.36M | +38.2% |
| FY2020 | Dec 31, 2020 | $338.30M | +29.6% |
| FY2019 | Dec 31, 2019 | $260.98M | +34.9% |
| FY2018 | Dec 31, 2018 | $193.45M | -2.5% |
| FY2017 | Dec 31, 2017 | $198.51M | +43.1% |
| FY2016 | Dec 31, 2016 | $138.73M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $43.76M | -56.7% |
| Q1 FY2026 | Mar 31, 2026 | $37.23M | -57.1% |
| Q4 FY2025 | Dec 31, 2025 | $225.61M | +78.1% |
| Q3 FY2025 | Sep 30, 2025 | $150.86M | +31.0% |
| Q2 FY2025 | Jun 30, 2025 | $101.01M | -22.4% |
| Q1 FY2025 | Mar 31, 2025 | $86.69M | -21.2% |
| Q4 FY2024 | Dec 31, 2024 | $126.66M | +27.1% |
| Q3 FY2024 | Sep 30, 2024 | $115.18M | +6.1% |
| Q2 FY2024 | Jun 30, 2024 | $130.23M | +11.0% |
| Q1 FY2024 | Mar 31, 2024 | $109.98M | +2.2% |
| Q4 FY2023 | Dec 31, 2023 | $99.65M | -13.7% |
| Q3 FY2023 | Sep 30, 2023 | $108.53M | -7.1% |
| Q2 FY2023 | Jun 30, 2023 | $117.32M | -3.4% |
| Q1 FY2023 | Mar 31, 2023 | $107.64M | +10.8% |
| Q4 FY2022 | Dec 31, 2022 | $115.52M | -9.7% |
| Q3 FY2022 | Sep 30, 2022 | $116.86M | +2.7% |
| Q2 FY2022 | Jun 30, 2022 | $121.40M | -1.5% |
| Q1 FY2022 | Mar 31, 2022 | $97.12M | -5.3% |
| Q4 FY2021 | Dec 31, 2021 | $127.86M | +19.7% |
| Q3 FY2021 | Sep 30, 2021 | $113.75M | +12.9% |
| Q2 FY2021 | Jun 30, 2021 | $123.20M | +78.6% |
| Q1 FY2021 | Mar 31, 2021 | $102.55M | +66.1% |
| Q4 FY2020 | Dec 31, 2020 | $106.81M | +43.1% |
| Q3 FY2020 | Sep 30, 2020 | $100.80M | +56.8% |
| Q2 FY2020 | Jun 30, 2020 | $68.96M | +6.2% |
| Q1 FY2020 | Mar 31, 2020 | $61.73M | +8.1% |
| Q4 FY2019 | Dec 31, 2019 | $74.65M | +17.4% |
| Q3 FY2019 | Sep 30, 2019 | $64.27M | +26.6% |
| Q2 FY2019 | Jun 30, 2019 | $64.95M | +49.1% |
| Q1 FY2019 | Mar 31, 2019 | $57.12M | +60.8% |
| Q4 FY2018 | Dec 31, 2018 | $63.60M | +19.7% |
| Q3 FY2018 | Sep 30, 2018 | $50.77M | -1.3% |
| Q2 FY2018 | Jun 30, 2018 | $43.55M | -19.5% |
| Q1 FY2018 | Mar 31, 2018 | $35.53M | -10.8% |
| Q4 FY2017 | Dec 31, 2017 | $53.14M | -61.7% |
| Q3 FY2017 | Sep 30, 2017 | $51.46M | – |
| Q2 FY2017 | Jun 30, 2017 | $54.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $39.84M | – |
| Q4 FY2016 | Dec 31, 2016 | $138.73M | – |
See a number that looks wrong?